In addition to GBM, a dose-escalation phase I trial (CTI: NCT00088061) to evaluate the safety and tissue distribution of the IL13-PE38QQR administered via CED in five children with diffuse intrinsic pontine glioma (DIPG) has been reported recently. Here, IL13 is linked to diffuse intrinsic pontine glioma.